Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.
Times cited: 36
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
British journal of cancer.
Times cited: 19